☆ 4.3 Review

Safety considerations in the management of hepatitis C and HIV co-infection

EXPERT OPINION ON DRUG SAFETY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Medicine, General & Internal

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2022 Recommendations of the International Antiviral Society-USA Panel

Rajesh T. Gandhi et al.

Summary: Based on new data, recommendations are provided to clinicians on the use of antiretroviral drugs for the treatment and prevention of HIV, as well as on laboratory monitoring, care of aging individuals with HIV, substance use disorder, and new challenges such as COVID-19 and monkeypox virus infection. The initiation of antiretroviral therapy as soon as possible after HIV diagnosis is recommended, along with addressing barriers to care and ensuring access to medication and adherence support. Advances in treatment and prevention of HIV have improved outcomes, but challenges and opportunities still exist.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Article Infectious Diseases

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study

Myroslava Nikolaichuk et al.

Summary: This study aimed to determine the usage of antiretroviral drugs (ARVs) according to European AIDS Clinical Society (EACS) guidelines in HIV/HCV coinfected patients treated with direct-acting antivirals (DAAs). The findings showed that more than one-third of patients received DAAs with potential ARV contraindications, but few received a contraindicated ARV. However, patients who received a contraindicated DAA and ARV combination still had a high rate of sustained virological response.

HIV MEDICINE (2023)

添加到收藏夹

Review Immunology

Viral hepatitis in persons living with HIV in the post-COVID era

Vicente Soriano et al.

Summary: Coinfection with hepatitis viruses A to E is frequent and causes significant morbidity and mortality in persons living with HIV (PLWH). Hepatitis A and E mainly produce acute self-limited episodes in poor income regions and non-vaccinated travelers. Chronic hepatitis B, C, and D are frequent in PLWH in highly endemic regions and globally in persons who inject drugs and men having sex with men. Rating: 8 out of 10.

AIDS REVIEWS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain

Jose-Manuel Ramos-Rincon et al.

Summary: Hospital admissions of individuals with HBV infection are increasing in Spain, and while hepatic decompensation events have declined, HBV-related liver cancer continues to rise. Oral antiviral therapies do not have any benefit on hepatitis delta.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Susceptibility to hepatitis B virus infection in adults living in Spain

Vicente Soriano et al.

Summary: In Spain, the proportion of adults vaccinated against hepatitis B is still low, with approximately 60% of adults at risk for hepatitis B. Therefore, it is recommended to conduct HBV serological testing and administer HBV vaccines or boosters to all adults.

LIVER INTERNATIONAL (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Acute hepatitis C virus infection: clinical update and remaining challenges

Chen-Hua Liu et al.

Summary: Acute hepatitis C virus (HCV) infection, with varying incidence rates globally, is most common in individuals who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus. Diagnosing acute HCV infection is challenging in immunocompromised, reinfected, and superinfected patients due to difficulties in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid. Clinical trials have recently shown the treatment benefits of direct-acting antivirals (DAAs). Early initiation of DAAs is recommended for acute HCV infection before spontaneous viral clearance, and shorter treatment durations can be effective. Standard DAA regimens have similar efficacy in treating HCV-reinfected patients and DAA-naive ones. For specific cases, such as HCV-viremic liver and non-liver solid organ transplant recipients, different treatment durations and courses of DAAs are suggested. Prophylactic HCV vaccines are currently unavailable, so prevention measures, harm reduction, safe sex, and vigilant surveillance after viral clearance are crucial for reducing HCV transmission. (Clin Mol Hepatol 2023;29:623-642)

CLINICAL AND MOLECULAR HEPATOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis

Hsuan-Yu Hung et al.

Summary: The study aimed to analyze the incidence of drug-induced liver injury of Glecaprevir/pibrentasvir (G/P) for chronic hepatitis C virus. It was found that drug-induced liver injury frequently occurred with G/P treatment, particularly hyperbilirubinemia in patients with cirrhosis. Despite this, G/P remains the primary therapy for CKD and end-stage renal disease (ESRD) patients due to its superior safety rate.

ANNALS OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

Chen-Hua Liu et al.

Summary: In patients with severe renal impairment and chronic hepatitis C virus infection, sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) for 12 weeks showed high effectiveness and safety, with high sustained virological response rates and minimal adverse events.

GUT (2022)

添加到收藏夹

Article Infectious Diseases

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis

Vicente Soriano et al.

Summary: Viral hepatitis is a significant global cause of mortality, with 1.4 million deaths each year. Hepatitis B and C account for 90% of these deaths, and the World Health Organization aims to eliminate viral hepatitis as a public health threat by 2030. While current antivirals can suppress viral replication, they cannot eliminate the virus from infected patients.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

Sarah Blach et al.

Summary: This study aims to evaluate the burden of hepatitis C virus (HCV) in 2020 and forecast the burden by 2030. Using literature review, Delphi process, and mathematical modelling, it estimated the global prevalence of viraemic HCV infection to be 0.7% in 2020, corresponding to 56.8 million infections. The findings suggest that the current efforts are not on track to achieve the global elimination targets by 2030.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

Lene Ryom et al.

Summary: In 2021, the EACS Guidelines were extensively updated and expanded to include new sections. The recommendations are available as a free app, in interactive web format, and as an online pdf.

HIV MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies

Jose-Manuel Ramos-Rincon et al.

Summary: Hospital admissions for HCV individuals have significantly declined in Spain since 2015, but the diagnosis of liver cancer continues to rise.

JOURNAL OF VIRAL HEPATITIS (2022)

添加到收藏夹

Article Microbiology

Real-life experience of hepatitis C treatment in a Spanish prison

Rosa Juana Tejera-Perez et al.

Summary: This study analyzed the clinical and epidemiological characteristics of HCV-infected residents of a Spanish prison who received antiviral treatment. The results showed that most of the inmates achieved a sustained virological response without significant complications. This provides an opportunity to reduce the burden of HCV infection, especially in high-risk populations.

REVISTA ESPANOLA DE QUIMIOTERAPIA (2022)

添加到收藏夹

Article Microbiology

Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases

Vicente Soriano et al.

Summary: Vaccines have been successful in fighting viruses, but challenges remain; Advances in antiviral drugs offer new hope for preventing and treating viral diseases; Ultra-long-acting antiviral drugs may be used as "chemical vaccines" in the future.

FUTURE MICROBIOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5

Chen-Hua Liu et al.

Summary: This review summarizes the updated knowledge regarding the epidemiology, natural history, public health perspectives of HCV in patients with CKD stage 4 or 5 and the performance of pan-genotypic DAAs in these patients. The prevalence and incidence of HCV are much higher in patients with CKD stage 4 or 5 than in the general population. Pan-genotypic DAAs show excellent efficacy and safety in treating HCV in these patients.

HEPATOLOGY INTERNATIONAL (2022)

添加到收藏夹

Article Multidisciplinary Sciences

An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression

Srijanee Das et al.

Summary: The treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy, but suboptimal adherence has led to the need for ultralong-acting antivirals. A recent study developed a new drug called NM1TFV, which demonstrated monthslong antiviral activities in mice and in laboratory experiments, providing proof of concept for a new therapeutic paradigm for HBV treatment and prevention.

SCIENCE ADVANCES (2022)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project

Claudio Borghi et al.

Summary: Orally administered direct-acting antivirals (DAAs) have significantly improved the chances of curing hepatitis C virus (HCV) infection. However, due to the potential drug-drug interactions (DDIs) in HCV patients who often take concomitant drugs, careful assessment and management are needed.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Lenacapavir: First Approval

Julia Paik

Summary: This article summarizes the milestones in the development of lenacapavir, a long-acting capsid inhibitor for the treatment of HIV-1 infection, leading to its first approval.

DRUGS (2022)

添加到收藏夹

Article Infectious Diseases

HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution

Francesco Pes et al.

Summary: DAA treatment in HIV-HCV co-infected patients resulted in high SVR12 rates and was well tolerated. An increase in CD4+ and CD8+ cell count was observed six months after completion of DAA treatment, particularly in patients with low CD4+ cell count at baseline.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

Brittney S. Sheena et al.

Summary: This study estimated the global, regional, and national prevalence of HBV, as well as mortality and DALYs due to HBV in 2019. It found a decline in HBV infection rates in different age groups, but an increase in HBV-related deaths. Many countries have reached the target for HBV infection rates in children, but targets for reducing deaths and cases have not been met, and progress needs to be accelerated to achieve the 2030 goals.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates

Sabela Lens et al.

Summary: The study shows that hepatitis C treatment for drug users at harm reduction centers not only leads to viral clearance, but also improves quality of life, reduces injection frequency, and risk practices. However, challenges such as low screening acceptance and high reinfection rates hinder the achievement of viral microelimination in this population.

JHEP REPORTS (2022)

添加到收藏夹

Article Immunology

Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

Laurent Cotte et al.

Summary: A significant shift in HCV epidemiology was observed in people living with HIV in France from 2012 to 2018, with a decrease in overall HCV prevalence but an increase in new infections among men who have sex with men (MSM), making MSM the primary group for HCV transmission in 2018.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Gail V. Matthews et al.

Summary: In this randomised study comparing a 6-week course to a 12-week course of sofosbuvir-velpatasvir for recent HCV infection, the shorter course did not meet the criteria for non-inferiority. The study was halted early on advice of the data safety and monitoring board due to lack of efficacy in the 6-week arm.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

The Changing Liver Transplant Recipient From Hepatitis C to Nonalcoholic Steatohepatitis and Alcohol

Ross Vyhmeister et al.

CLINICS IN LIVER DISEASE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy

Chen-Hua Liu et al.

Summary: The nephrotoxicity of sofosbuvir (SOF) on HIV/HCV-coinfected patients receiving antiretroviral therapy (ART) remains controversial. Participants on TFV-based ART had a higher eGFR decline than those on TFV-free ART during DAA treatment. However, after discontinuation of DAAs, the eGFR changes did not differ significantly between groups.

JOURNAL OF VIRAL HEPATITIS (2021)

添加到收藏夹

Review Medicine, General & Internal

Hepatitis C: A Pharmacological Therapeutic Update

Sonia Santander Ballestin et al.

Summary: Newly introduced combination therapies for hepatitis C exhibit high safety, effectiveness, and shorter treatment duration, proving to be effective for previously treated or compensated cirrhotic patients.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naive Hepatitis C Virus Infection

Tasuku Hara et al.

Summary: A 49-year-old man with chronic hepatitis C infection underwent treatment with glecaprevir plus pibrentasvir (G/P) and developed acute liver injury six weeks later, which was successfully mitigated by discontinuing the treatment and implementing rigorous medical protocols including plasma exchange and hemodiafiltration. It was also discovered that the patient had allergies to two other drugs, highlighting the importance of careful observation in such cases with a history of drug allergy.

INTERNAL MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach

Edward R. Cachay et al.

Summary: The study demonstrates that treating HIV and HCV co-infected patients with direct-acting antivirals can yield excellent outcomes, with an impressive 91% achieving sustained viral response. Integrating sub-specialty services can further improve treatment success rates for patients with histories of decompensated liver disease.

JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modelling approach

Mathieu Castry et al.

Summary: Combining test-and-treat and risk-reduction strategies could significantly impact the HCV epidemic among MSM living with HIV, paving the way for the elimination of HCV among this population.

GUT (2021)

添加到收藏夹

Article Immunology

Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals

Matthew P. Kosloski et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection

Marianne Martinello et al.

HEPATOLOGY (2020)

添加到收藏夹

Review Immunology

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV

Robert C. Bollinger et al.

LANCET HIV (2020)

添加到收藏夹

Article Chemistry, Physical

A year-long extended release nanoformulated cabotegravir prodrug

Tanmay A. Kulkarni et al.

NATURE MATERIALS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL recommendations on treatment of hepatitis C: Final update of the series

Jean-Michel Pawlotsky et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Immunology

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus

Edward R. Cachay et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Sergio M. Borgia et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe

H. Stoever et al.

BMC PUBLIC HEALTH (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection

C-H Liu et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Immunology

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Erik Mogalian et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Immunology

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Juergen K. Rockstroh et al.

CLINICAL INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Should we treat acute hepatitis C? A decision and cost-effectiveness analysis

Emily D. Bethea et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population

Cameron Sikavi et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV

Tomoko Tadokoro et al.

INTERNAL MEDICINE (2018)

添加到收藏夹

Article Substance Abuse

Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries

Rob Bielen et al.

HARM REDUCTION JOURNAL (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis

Marcus M. Muecke et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)

添加到收藏夹

Article Infectious Diseases

High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice

J. Macias et al.

HIV MEDICINE (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model

Nat Wright et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

Vicente Soriano et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Drug interactions in HIV-infected patients treated for hepatitis C

Vicente Soriano et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Paul Kwo et al.

GASTROENTEROLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Ira M. Jacobson et al.

GASTROENTEROLOGY (2017)

添加到收藏夹

Letter Gastroenterology & Hepatology

Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil

Yuanjun Shen et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

Paul Y. Kwo et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

Cheng Wang et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)

添加到收藏夹

Review Immunology

From One Syndrome to Many: Incorporating Geriatric Consultation Into HIV Care

Harjot K. Singh et al.

CLINICAL INFECTIOUS DISEASES (2017)

添加到收藏夹

Article Immunology

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

David Wyles et al.

CLINICAL INFECTIOUS DISEASES (2017)

添加到收藏夹

Review Infectious Diseases

Hepatitis C cure with antiviral therapy - benefits beyond the liver

Vincent Soriano et al.

ANTIVIRAL THERAPY (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

Erik Mogalian et al.

CLINICAL PHARMACOKINETICS (2016)

添加到收藏夹

Article Medicine, General & Internal

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial

Gregory J. Dore et al.

ANNALS OF INTERNAL MEDICINE (2016)

添加到收藏夹

Article Oncology

Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment

C. S. Voican et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Virology

Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge

Anne De Monte et al.

JOURNAL OF CLINICAL VIROLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C

Aude Desnoyer et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Review Infectious Diseases

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis

Lucy Platt et al.

LANCET INFECTIOUS DISEASES (2016)

添加到收藏夹

Review Medicine, General & Internal

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis

Huilian Wang et al.

MEDICINE (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection

Kristen L. Bunnell et al.

PHARMACOTHERAPY (2016)

添加到收藏夹

Article Immunology

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection

Marianne Martinello et al.

OPEN FORUM INFECTIOUS DISEASES (2016)

添加到收藏夹

Review Pharmacology & Pharmacy

Treatment Considerations for Unique Patient Populations With HCV Genotype I Infection

Kimberly A. Toussaint-Miller et al.

ANNALS OF PHARMACOTHERAPY (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C

Yousef Fazel et al.

EXPERT OPINION ON DRUG SAFETY (2015)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era?

Norah Terrault

HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

Saleh A. Alqahtani et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Gastroenterology & Hepatology

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Tariq Ahmad et al.

HEPATOLOGY (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Treatment of hepatitis C in difficult-to-treat patients

Peter Ferenci

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

G. R. Foster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Infectious Diseases

Emerging Challenges in Managing Hepatitis B in HIV Patients

Vincent Soriano et al.

CURRENT HIV/AIDS REPORTS (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection

R. S. Koff

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

添加到收藏夹

Article Medicine, General & Internal

Hepatic Decompensation in Antiretroviral-Treated Patients Co-Infected With HIV and Hepatitis C Virus Compared With Hepatitis C Virus-Monoinfected Patients A Cohort Study

Vincent Lo Re et al.

ANNALS OF INTERNAL MEDICINE (2014)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Towards hepatitis C eradication from the HIV-infected population

Pablo Barreiro et al.

ANTIVIRAL RESEARCH (2014)

添加到收藏夹

Article Infectious Diseases

Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies

Pablo Labarga et al.

ANTIVIRAL THERAPY (2014)

添加到收藏夹

Review Infectious Diseases

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

Drosos E. Karageorgopoulos et al.

CURRENT OPINION IN INFECTIOUS DISEASES (2014)

添加到收藏夹

Article Health Policy & Services

Reducing Barriers to Hepatitis C Treatment among Drug Users: An Integrated Hepatitis C Peer Education and Support Program

Robert J. Roose et al.

JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management

Jose V. Fernandez-Montero et al.

EXPERT OPINION ON DRUG SAFETY (2013)

添加到收藏夹

Letter Medicine, General & Internal

Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan

Chun-Ju Chiang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

添加到收藏夹

Review Gastroenterology & Hepatology

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions

David Burger et al.

JOURNAL OF HEPATOLOGY (2013)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The P-Glycoprotein Transport System and Cardiovascular Drugs

Jeffrey D. Wessler et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain

Clara Sanchez et al.

LIVER INTERNATIONAL (2013)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

VIRAL HEPATITIS Treating hepatitis C in injection drug users

Vincent Soriano et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)

添加到收藏夹

Review Gastroenterology & Hepatology

Drug-drug interactions during antiviral therapy for chronic hepatitis C

Jennifer J. Kiser et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)

添加到收藏夹

Article Public, Environmental & Occupational Health

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

Charlotte Lewden et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)

添加到收藏夹

Article Immunology

Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study

Mei-Hsuan Lee et al.

JOURNAL OF INFECTIOUS DISEASES (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

Inmaculada Jimenez-Nacher et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany-A Case-Control Study

Axel J. Schmidt et al.

PLOS ONE (2011)

添加到收藏夹

Article Immunology

Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

Pablo Labarga et al.

AIDS (2009)

添加到收藏夹

Article Infectious Diseases

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Vincent Soriano et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)

添加到收藏夹

Article Public, Environmental & Occupational Health

Hepatitis c virus activation in HIV-infected patients initiating highly active antiretroviral therapy

H. Nina Kim et al.

AIDS PATIENT CARE AND STDS (2007)

添加到收藏夹

Article Immunology

Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: Lopinavir-ritonavir versus nelfinavir

KE Sherman et al.

CLINICAL INFECTIOUS DISEASES (2005)

添加到收藏夹

Review Pharmacology & Pharmacy

Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense

EM Leslie et al.

TOXICOLOGY AND APPLIED PHARMACOLOGY (2005)

添加到收藏夹

Article Immunology

Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution

L Martín-Carbonero et al.

AIDS (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.